Cytel Inc acquires the SDS Group

The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consulting company SDS Life Science.

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.

Business Sweden’s new team is rolling out the blue-yellow carpet

According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"

The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.

Ny metod för mikroskopi öppnar genväg till nya läkemedel

Forskare vid Chalmers har utvecklat en helt ny mikroskopiteknik för att kunna studera de minsta biologiska partiklarna i sitt naturliga tillstånd – och därmed öppna vägar för snabbare utveckling av nya läkemedel och vaccin.

Anna Törner: To kill your darlings

Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of exciting results and perhaps a publication in a high-impact journal,” she writes in a column.

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

Søren Bregenholt omvald som ordförande i MVA

Under Medicon Valley Alliance årsstämma fick styrelsen förnyat förtroende och valdes om.

Miljonstöd till 14 life science-projekt för bättre hälsa

Nya tekniker för fixering av handfrakturer, AI-prediktion av blodtrycksfall och tidig detektion av bukspottkörtelcancer finns bland de 14 projekt för bättre hälsa som får miljonstöd av innovationsprogrammen Swelife och Medtech4health.

Lucy Robertshaw: Are we in the perfect storm?

“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of people who are presenting with chronic diseases that need to access healthcare again”, writes

Björn Ursing: Physicians new role in AI driven healthcare

”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians changes in the era of AI.

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.

Oasmia tar in 151 miljoner – och byter namn

Styrelsen i cancerforskningsföretaget Oasmia har beslutat om en nyemission på 151 miljoner kronor. Samtidigt föreslås ett namnbyte av företaget till Vivesto.

Pharma Outsourcing igång på Stockholm Waterfront

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Samtycke från patient – i många fall inte tillräckligt för databehandling

Vilka är konsekvenserna av att den Europeiska dataskyddsstyrelsen uttalat att försökspersoner i de flesta fall inte kan samtycka till hantering av data rörande dem? Advokaterna på Cirio Advokatbyrå reder ut.

Medtechföretag anklagas för bluff

Blankarbolag sågar medicinteknikbolaget Nano X Imaging.